{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:47:44Z","timestamp":1784260064274,"version":"3.55.0"},"reference-count":187,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BST"],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.5582\/bst.2025.01012","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T22:12:10Z","timestamp":1742249530000},"page":"309-327","source":"Crossref","is-referenced-by-count":4,"title":["Multimodal treatment of colorectal liver metastases: Where are we? Current strategies and future perspectives"],"prefix":"10.5582","volume":"19","author":[{"given":"Caterina","family":"Accardo","sequence":"first","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Vella","sequence":"additional","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"di Francesco","sequence":"additional","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Istituto di Ricovero e Cura a Carattere Scientifico- Istituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Calamia","sequence":"additional","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tropea","sequence":"additional","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Bonsignore","sequence":"additional","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Li Petri","sequence":"additional","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Gruttadauria","sequence":"additional","affiliation":[{"name":"Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, Istituto di Ricovero e Cura a Carattere ScientificoIstituto Mediterraneo per i Trapianti e Terapie ad alta specializzazione (IRCCS-ISMETT), University of Pittsburgh Medical Center (UPMC), Palermo, Italy."},{"name":"Department of Surgery and Medical and Surgical Specialties, University of Catania, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. International Agency for Research on Cancer WHO, Others. Estimated number of deaths in 2020, worldwide, both sexes, all ages. Avaliable at: <i>https:\/\/gco.iarc.fr\/today\/online-analysis-pie.2020<\/i>. (accessed March 9, 2020)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol. 2019; 10:1274-1298.","DOI":"10.21037\/jgo.2019.08.06"},{"key":"3","unstructured":"3. Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunv\u00e9n P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery. 1990; 107:521-527."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg. 2000; 232:777-785.","DOI":"10.1097\/00000658-200012000-00006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Schnitzbauer AA, Lang SA, Goessmann H <i>et al.<\/i> Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012; 255:405-414.","DOI":"10.1097\/SLA.0b013e31824856f5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Adam R, Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019; 3:50-56.","DOI":"10.1002\/ags3.12227"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ivey GD, Johnston FM, Azad NS, Christenson ES, Lafaro KJ, Shubert CR. Current surgical management strategies for colorectal cancer liver metastases. Cancers (Basel). 2022; 14:1063.","DOI":"10.3390\/cancers14041063"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Chandra P, Sacks GD. Contemporary Surgical Management of Colorectal Liver Metastases. Cancers (Basel). 2024; 16:941.","DOI":"10.3390\/cancers16050941"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Krell RW, Reames BN, Hendren S, Frankel TL, Pawlik TM, Chung M, Kwon D, Wong SL. Surgical referral for colorectal liver metastases: A population-based survey. Ann Surg Oncol. 2015; 22:2179-2194.","DOI":"10.1245\/s10434-014-4318-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wei AC, Jarnagin WR. Questioning why more patients with colorectal liver metastases are not referred for metastasectomy. JAMA Surg. 2020; 155:909-910.","DOI":"10.1001\/jamasurg.2020.1460"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ignatavicius P, Oberkofler CE, Chapman WC <i>et al.<\/i> Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: A throw of the Dice? Ann Surg. 2020; 272:715-722.","DOI":"10.1097\/SLA.0000000000004331"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Siriwardena AK, Serrablo A, Fretland \u00c5A <i>et al.<\/i> Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE. Br J Surg. 2023; 110:1161-1170.","DOI":"10.1093\/bjs\/znad124"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, Ijzermans J, Hubert C, Ruers T, Capussotti L, Ouellet JF, Laurent C, Cugat E, Colombo PE, Milicevic M. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010; 252:774-787.","DOI":"10.1097\/SLA.0b013e3181fcf3e3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34:10-32.","DOI":"10.1016\/j.annonc.2022.10.003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999; 230:309-321.","DOI":"10.1097\/00000658-199909000-00004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cohen R, Platell CF. Metachronous colorectal cancer metastasis: Who, what, when and what to do about it. J Surg Oncol. 2024; 129:71-77.","DOI":"10.1002\/jso.27400"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Beets G, Sebag-Montefiore D, Andritsch E <i>et al.<\/i> ECCO essential requirements for quality cancer care: Colorectal cancer. A critical review. Crit Rev Oncol Hematol. 2017; 110:81-93.","DOI":"10.1016\/j.critrevonc.2016.12.001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Osterlund P, Salminen T, Soveri L-M <i>et al.<\/i> Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study. Lancet Reg Health Eur. 2021; 3:100049.","DOI":"10.1016\/j.lanepe.2021.100049"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Rees M, Tekkis PP, Welsh FK, O&apos;Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008; 247:125-35.","DOI":"10.1097\/SLA.0b013e31815aa2c2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Dijkstra M, Nieuwenhuizen S, Puijk RS, Timmer FEF, Geboers B, Schouten EAC, Opperman J, Scheffer HJ, de Vries JJJ, Versteeg KS, Lissenberg-Witte BI, van den Tol MP, Meijerink MR. Primary tumor sidedness, RAS and BRAF mutations and MSI status as prognostic factors in patients with colorectal liver metastases treated with surgery and thermal ablation: results from the Amsterdam Colorectal Liver Met Registry (AmCORE). Biomedicines. 2021; 9:962.","DOI":"10.3390\/biomedicines9080962"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Worni M, Shah KN, Clary BM. Colorectal cancer with potentially resectable hepatic metastases: optimizing treatment. Curr Oncol Rep. 2014; 16:407.","DOI":"10.1007\/s11912-014-0407-z"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Phelip JM, Mineur L, De la Fouchardi\u00e8re C, Chatelut E, Quesada JL, Roblin X, Pezet D, Mendoza C, Buc E, Rivoire M. High resectability rate of initially unresectable colorectal liver metastases after UGT1A1-Adapted High-Dose irinotecan combined with LV5FU2 and cetuximab: A multicenter phase II study (ERBIFORT). Ann Surg Oncol. 2016; 23:2161-2166.","DOI":"10.1245\/s10434-015-5072-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ichida H, Mise Y, Ito H, Ishizawa T, Inoue Y, Takahashi Y, Shinozaki E, Yamaguchi K, Saiura A. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. World J Surg Oncol. 2019; 17:100.","DOI":"10.1186\/s12957-019-1641-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nieuwenhuizen S, Puijk RS, van den Bemd B <i>et al.<\/i> Resectability and ablatability criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary consensus document from the COLLISION Trial Group. Cancers (Basel). 2020; 12:1779.","DOI":"10.3390\/cancers12071779"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Pietrantonio F, Di Bartolomeo M, Cotsoglou C <i>et al.<\/i> Perioperative triplet chemotherapy and cetuximab in patients with RAS wild type high recurrence risk or borderline resectable colorectal cancer liver metastases. Clin Colorectal Cancer. 2017; 16:e191-e198.","DOI":"10.1016\/j.clcc.2016.09.007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ekberg H, Tranberg KG, Andersson R, Lundstedt C, H\u00e4gerstrand I, Ranstam J, Bengmark S. Determinants of survival in liver resection for colorectal secondaries. Br J Surg. 1986; 73:727-731.","DOI":"10.1002\/bjs.1800730917"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Vigan\u00f2 L, Capussotti L, Majno P, Toso C, Ferrero A, De Rosa G, Rubbia-Brandt L, Mentha G. Liver resection in patients with eight or more colorectal liver metastases. Br J Surg. 2015; 102:92-101.","DOI":"10.1002\/bjs.9680"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Allard MA, Adam R, Giuliante F <i>et al.<\/i> Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer. 2017; 117:604-611.","DOI":"10.1038\/bjc.2017.218"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Huiskens J, Bolhuis K, Engelbrecht MR, De Jong KP, Kazemier G, Liem MS, Verhoef C, de Wilt JH, Punt CJ, van Gulik TM; Dutch colorectal cancer group. Outcomes of resectability assessment of the Dutch Colorectal Cancer Group Liver Metastases Expert Panel. J Am Coll Surg. 2019; 229:523-532.e2.","DOI":"10.1016\/j.jamcollsurg.2019.08.1445"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E; Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012; 17:1225-1239.","DOI":"10.1634\/theoncologist.2012-0121"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Bismuth H, Adam R, L\u00e9vi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996; 224:509-522.","DOI":"10.1097\/00000658-199610000-00009"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005; 23:9243-9249.","DOI":"10.1200\/JCO.2005.07.740"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Adam R, Wicherts DA, de Haas RJ, Ciacio O, L\u00e9vi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009; 27:1829-1835.","DOI":"10.1200\/JCO.2008.19.9273"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Folprecht G, Gruenberger T, Bechstein W <i>et al.<\/i> Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014; 25:1018-25.","DOI":"10.1093\/annonc\/mdu088"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Huiskens J, van Gulik TM, van Lienden KP <i>et al.<\/i> Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 2015; 15:365.","DOI":"10.1186\/s12885-015-1323-9"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sugiyama M, Uehara H, Shin Y, Shiokawa K, Fujimoto Y, Mano Y, Komoda M, Nakashima Y, Sugimachi K, Yamamoto M, Morita M, Toh Y. Indications for conversion hepatectomy for initially unresectable colorectal cancer with liver metastasis. Surg Today. 2022; 52:633-642.","DOI":"10.1007\/s00595-021-02403-5"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, Kunstlinger F, Levi F, Bismuth F. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001; 8:347-53.","DOI":"10.1007\/s10434-001-0347-3"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, Jarnagin WR, Patel D, D&apos;Angelica M. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009; 27:3465-3471.","DOI":"10.1200\/JCO.2008.20.1301"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Damato A, Ghidini M, Dottorini L, Tomasello G, Iaculli A, Ghidini A, Luciani A, Petrelli F. Chemotherapy duration for various indications in colorectal cancer: a review. Curr Oncol Rep. 2023; 25:341-352.","DOI":"10.1007\/s11912-023-01378-5"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Innominato PF, Cailliez V, Allard M-A <i>et al.<\/i> Impact of preoperative chemotherapy features on patient outcomes after hepatectomy for initially unresectable colorectal cancer liver metastases: A LiverMetSurvey Analysis. Cancers (Basel). 2022; 14:4340.","DOI":"10.3390\/cancers14174340"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Calistri L, Rastrelli V, Nardi C, Maraghelli D, Vidali S, Pietragalla M, Colagrande S. Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis. World J Gastroenterol. 2021; 27:7866-7893.","DOI":"10.3748\/wjg.v27.i46.7866"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Donati F, Cioni D, Guarino S, Mazzeo ML, Neri E, Boraschi P. Chemotherapy-Induced liver injury in patients with colorectal liver metastases: Findings from MR Imaging. Diagnostics (Basel). 2022; 12:867.","DOI":"10.3390\/diagnostics12040867"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Morris VK, Kennedy EB, Baxter NN <i>et al.<\/i> Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023; 41:678-700.","DOI":"10.1200\/JCO.22.01690"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010; 11:845-852.","DOI":"10.1016\/S1470-2045(10)70175-3"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023; 24:757-771.","DOI":"10.1016\/S1470-2045(23)00219-X"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Andr\u00e9 T, Shiu K-K, Kim TW <i>et al.<\/i> Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383:2207-2218.","DOI":"10.1056\/NEJMoa2017699"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Heinemann V, von Weikersthal LF, Decker T <i>et al.<\/i> FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer. 2021; 124:587-594.","DOI":"10.1038\/s41416-020-01140-9"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Brul\u00e9 SY, Jonker DJ, Karapetis CS, O&apos;Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015; 51:1405-1414.","DOI":"10.1016\/j.ejca.2015.03.015"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Yaeger R, Uboha NV, Pelster MS <i>et al.<\/i> Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024; 14:982-993.","DOI":"10.1158\/2159-8290.CD-24-0217"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Sorbye H, Mauer M, Gruenberger T <i>et al.<\/i> Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012; 255:534-539.","DOI":"10.1097\/SLA.0b013e3182456aa2"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Adam R, de Gramont A, Figueras J <i>et al.<\/i> Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015; 41:729-741.","DOI":"10.1016\/j.ctrv.2015.06.006"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Chen FL, Wang YY, Liu W, Xing BC. Neoadjuvant chemotherapy improves overall survival in resectable colorectal liver metastases patients with high clinical risk scores-- A retrospective, propensity score matching analysis. Front Oncol. 2022; 12:973418.","DOI":"10.3389\/fonc.2022.973418"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Ninomiya M, Emi Y, Motomura T, Tomino T, Iguchi T, Kayashima H, Harada N, Uchiyama H, Nishizaki T, Higashi H, Kuwano H. Efficacy of neoadjuvant chemotherapy in patients with high-risk resectable colorectal liver metastases. Int J Clin Oncol. 2021; 26:2255-2264.","DOI":"10.1007\/s10147-021-02024-5"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Burasakarn P, Hongjinda S, Fuengfoo P, Thienhiran A. Neoadjuvant chemotherapy versus upfront surgery for resectable colorectal liver metastases: A systemic review and meta\u2010analysis. Surg Pract. 2024; 28:16\u201026.","DOI":"10.1111\/1744-1633.12662"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Bernardi L, Roesel R, Aghayan DL, Majno-Hurst PE, De Dosso S, Cristaudi A. Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma? Cancer Treat Rev. 2024; 124:102696.","DOI":"10.1016\/j.ctrv.2024.102696"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Nishioka Y, Shindoh J, Yoshioka R, Gonoi W, Abe H, Okura N, Yoshida S, Sakamoto Y, Hasegawa K, Fukayama M, Kokudo N. Clinical Impact of Preoperative Chemotherapy on Microscopic Cancer Spread Surrounding Colorectal Liver Metastases. Ann Surg Oncol. 2017; 24:2326-2333.","DOI":"10.1245\/s10434-017-5845-z"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Laurent C, Adam JP, Denost Q, Smith D, Saric J, Chiche L.Significance of R1 Resection for Advanced Colorectal Liver Metastases in the Era of Modern Effective Chemotherapy. World J Surg. 2016; 40:1191-1199.","DOI":"10.1007\/s00268-016-3404-6"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Jiang YJ, Zhou SC, Chen JH, Liang JW. Oncological outcomes of neoadjuvant chemotherapy in patients with resectable synchronous colorectal liver metastasis: A result from a propensity score matching study. Front Oncol. 2022; 12:951540.","DOI":"10.3389\/fonc.2022.951540"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Noda T, Takahashi H, Tei M <i>et al.<\/i> Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi-institutional retrospective study. Ann Gastroenterol Surg. 2022; 7:479-490.","DOI":"10.1002\/ags3.12631"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Liu W, Jin KM, Zhang MH, Bao Q, Liu M, Xu D, Wang K, Xing BC. Recurrence prediction by circulating tumor DNA in the patient with colorectal liver metastases after hepatectomy: A prospective biomarker study. Ann Surg Oncol. 2023; 30:4916-4926.","DOI":"10.1245\/s10434-023-13362-1"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Jones RP, Pugh SA, Graham J, Primrose JN, Barriuso J. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. Eur J Cancer. 2021; 144:368-381.","DOI":"10.1016\/j.ejca.2020.11.025"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Ayez N, van der Stok EP, Gr\u00fcnhagen DJ, Rothbarth J, van Meerten E, Eggermont AM, Verhoef C. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. Eur J Surg Oncol. 2015; 41:859-867.","DOI":"10.1016\/j.ejso.2015.04.012"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Engstrand J, Sterner J, Hasselgren K, Stromberg C, Sturesson C. Treatment intention and outcome in patients with simultaneously diagnosed liver and lung metastases from colorectal cancer. Eur J Surg Oncol. 2022; 48:1799-1806.","DOI":"10.1016\/j.ejso.2022.03.006"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Matsumura M, Yamashita S, Ishizawa T, Akamatsu N, Kaneko J, Arita J, Nakajima J, Kokudo N, Hasegawa K. Oncological benefit of complete metastasectomy for simultaneous colorectal liver and lung metastases. Am J Surg. 2020; 219:80-87.","DOI":"10.1016\/j.amjsurg.2019.06.007"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Handy JR, Bremner RM, Crocenzi TS, Detterbeck FC, Fernando HC, Fidias PM, Firestone S, Johnstone CA, Lanuti M, Litle VR, Kesler KA, Mitchell JD, Pass HI, Ross HJ, Varghese TK. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. 2019; 107:631-649.","DOI":"10.1016\/j.athoracsur.2018.10.028"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Mise Y, Mehran RJ, Aloia TA, Vauthey JN. Simultaneous lung resection <i>via<\/i> a transdiaphragmatic approach in patients undergoing liver resection for synchronous liver and lung metastases. Surgery. 2014; 156:1197-1203.","DOI":"10.1016\/j.surg.2014.04.050"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. De Bellis M, Kawaguchi Y, Duwe G, Tran Cao HS, Mehran RJ, Vauthey JN. Short- and long-term outcomes of a transdiaphragmatic approach for simultaneous resection of colorectal liver and lung metastases. J Gastrointest Surg. 2021; 25:641-649.","DOI":"10.1007\/s11605-020-04828-8"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Abdel Jalil R, Abou Chaar MK, Shihadeh OM, Al-Qudah O, Gharaibeh A, Aldimashki L, Dabous A, Ghanem R, Al-Edwan A. Transdiaphragmatic single-port video-assisted thoracoscopic surgery; a novel approach for pulmonary metastasectomy through laparotomy incision - case series. J Cardiothorac Surg. 2021; 16:18.","DOI":"10.1186\/s13019-021-01393-2"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Lerut P, Nuytens F, D&apos;Hondt M. Combined Minimal Invasive Transdiaphragmatic Resections of Peripheral Colorectal Lung Metastases in Patients Undergoing Laparoscopic Liver Resections. Ann Surg Oncol. 2016; 23:885.","DOI":"10.1245\/s10434-016-5304-2"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Engstrand J, Taflin H, Rystedt JL, Hemmingsson O, Urdzik J, Sandstr\u00f6m P, Bj\u00f6rnsson B, Hasselgren K. The resection rate of synchronously detected liver and lung metastasis from colorectal cancer is low-a national registry-based study. Cancers (Basel). 2023; 15:1434.","DOI":"10.3390\/cancers15051434"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Jeong S, Heo JS, Park JY, Choi DW, Choi SH. Surgical resection of synchronous and metachronous lung and liver metastases of colorectal cancers. Ann Surg Treat Res. 2017; 92:82-89.","DOI":"10.4174\/astr.2017.92.2.82"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Miller G, Biernacki P, Kemeny NE, Gonen M, Downey R, Jarnagin WR, D&apos;Angelica M, Fong Y, Blumgart LH, DeMatteo RP. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg. 2007; 205:231-238.","DOI":"10.1016\/j.jamcollsurg.2007.04.039"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Lee SH, Kim SH, Lim JH, Kim SH, Lee JG, Kim DJ, Choi GH, Choi JS, Kim KS. Aggressive surgical resection for concomitant liver and lung metastasis in colorectal cancer. Korean J Hepatobiliary Pancreat Surg. 2016; 20:110-115.","DOI":"10.14701\/kjhbps.2016.20.3.110"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Mise Y, Kopetz S, Mehran RJ, Aloia TA, Conrad C, Brudvik KW, Taggart MW, Vauthey JN. Is complete liver resection without resection of synchronous lung metastases justified? Ann Surg Oncol. 2015; 22:1585-1592.","DOI":"10.1245\/s10434-014-4207-3"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Chun YS, Mehran RJ, Tzeng C-WD, Kee BK, Dasari A, Sepesi B, Conrad C, Aloia TA, Kopetz S, Vauthey JN. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma. J Clin Orthod. 35: TPS3625. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.TPS362","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3625"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Giuliante F, Vigan\u00f2 L, De Rose AM <i>et al.<\/i> Liver-First Approach for Synchronous Colorectal Metastases: Analysis of 7360 Patients from the LiverMetSurvey Registry. Ann Surg Oncol. 2021; 28:8198-8208.","DOI":"10.1245\/s10434-021-10220-w"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Addeo P, Foguenne M, Guerra M, Cusumano C, Paul C, Faitot F, Fiore L, De Mathelin P, Bachellier P. Predicting Limited Survival After Resection of Synchronous Colorectal Liver Metastases: a Propensity Score Matched Comparison Between The Primary First And The Simultaneous Strategy. J Gastrointest Surg. 2023; 27:1141-1151.","DOI":"10.1007\/s11605-023-05633-9"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Fr\u00fchling P, Str\u00f6mberg C, Isaksson B, Urdzik J. A comparison of the simultaneous, liver-first, and colorectal-first strategies for surgical treatment of synchronous colorectal liver metastases at two major liver-surgery institutions in Sweden. HPB (Oxford). 2023; 25:26-36.","DOI":"10.1016\/j.hpb.2022.09.001"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Takeda K, Kikuchi Y, Sawada YU, Kumamoto T, Watanabe J, Kuniski C, Misumi T, Endo I. Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases. Anticancer Res. 2022; 42:5497-5505.","DOI":"10.21873\/anticanres.16055"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Hasegawa K, Saiura A, Takayama T <i>et al.<\/i> Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial. PLoS One. 2016; 11:e0162400.","DOI":"10.1371\/journal.pone.0162400"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Kanemitsu Y, Shimizu Y, Mizusawa J <i>et al.<\/i> Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial. J Clin Oncol. 2021; 39:3789-3799.","DOI":"10.1200\/JCO.21.01032"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Kobayashi S, Beppu T, Honda G <i>et al.<\/i> Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases-a Japanese Nationwide Survey. J Gastrointest Surg. 2020; 24:1244-1260.","DOI":"10.1007\/s11605-019-04250-9"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Satake H, Hashida H, Tanioka H <i>et al.<\/i> Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases. Oncologist. 2021; 26:e1125-e1132.","DOI":"10.1002\/onco.13816"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Van Cutsem E, Cervantes A, Adam R <i>et al.<\/i> ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27:1386-1422.","DOI":"10.1093\/annonc\/mdw235"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Yoshino T, Arnold D, Taniguchi H <i>et al.<\/i> Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018; 29:44-70.","DOI":"10.1093\/annonc\/mdx738"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Kelm M, Schollbach J, Anger F, Wiegering A, Klein I, Germer CT, Schlegel N, Kunzmann V, L\u00f6b S. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study. BMC Cancer. 2021; 21:490.","DOI":"10.1186\/s12885-021-07941-2"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Pan Z, Peng J, Lin J, Chen G, Wu X, Lu Z, Deng Y, Zhao Y, Sui Q, Wan D. Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection? Cancer Commun (Lond). 2018; 38:29.","DOI":"10.1186\/s40880-018-0298-8"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Nakai T, Ishikawa H, Tokoro T, Okuno K. The clinical risk score predicts the effectiveness of adjuvant chemotherapy for colorectal liver metastasis. World J Surg. 2015; 39:1527-1536.","DOI":"10.1007\/s00268-015-2980-1"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Kataoka K, Mori K, Nakamura Y <i>et al.<\/i> Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol. 2024; 35:1015-1025.","DOI":"10.1016\/j.annonc.2024.08.2240"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Kamal Y, Schmit SL, Frost HR, Amos CI. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Immunotherapy. 2020; 12:1083-1100.","DOI":"10.2217\/imt-2020-0026"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Rodriguez J, Casta\u00f1\u00f3n E, Perez-Gracia JL <i>et al.<\/i> A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis. J Immunother Cancer. 2018; 6:96.","DOI":"10.1186\/s40425-018-0405-z"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Zhang C, Wang Z, Yang Z <i>et al.<\/i> Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA<sup>+<\/sup> Metastatic Colorectal Cancers. Mol Ther. 2017; 25:1248-1258.","DOI":"10.1016\/j.ymthe.2017.03.010"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Sahu SS, Dey S, Nabinger SC, Jiang G, Bates A, Tanaka H, Liu Y, Kota J. The Role and Therapeutic Potential of miRNAs in Colorectal Liver Metastasis. Sci Rep. 2019; 9:15803.","DOI":"10.1038\/s41598-019-52225-2"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Balacescu O, Sur D, Cainap C, Visan S, Cruceriu D, Manzat-Saplacan R, Muresan MS, Balacescu L, Lisencu C, Irimie A. The Impact of miRNA in Colorectal Cancer Progression and Its Liver Metastases. Int J Mol Sci. 2018; 19:3711.","DOI":"10.3390\/ijms19123711"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Zhang J, Wu K, Shi C, Li G. Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light. Curr Treat Options Oncol. 2022; 23:1777-1792.","DOI":"10.1007\/s11864-022-01027-2"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Bouzo BL, Lores S, Jatal R, Alijas S, Alonso MJ, Conejos-S\u00e1nchez I, de la Fuente M. Sphingomyelin nanosystems loaded with uroguanylin and etoposide for treating metastatic colorectal cancer. Sci Rep. 2021; 11:17213.","DOI":"10.1038\/s41598-021-96578-z"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Heinrich S. The current role of liver surgery in the treatment of colorectal liver metastases. Hepatobiliary Surg Nutr. 2019; 8:552-554.","DOI":"10.21037\/hbsn.2019.05.02"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000; 7:643-650.","DOI":"10.1007\/s10434-000-0643-3"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN; Americas Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013; 15:91-103.","DOI":"10.1111\/j.1477-2574.2012.00557.x"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Mohammad WM, Martel G, Mimeault R, Fairfull-Smith RJ, Auer RC, Balaa FK. Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB (Oxford). 2012; 14:291-297.","DOI":"10.1111\/j.1477-2574.2012.00440.x"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011; 29:1083-1090.","DOI":"10.1200\/JCO.2010.32.6132"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Giuliante F, Ardito F, Ferrero A, Aldrighetti L, Ercolani G, Grande G, Ratti F, Giovannini I, Federico B, Pinna AD, Capussotti L, Nuzzo G. Tumor progression during preoperative chemotherapy predicts failure to complete 2-stage hepatectomy for colorectal liver metastases: results of an Italian multicenter analysis of 130 patients. J Am Coll Surg. 2014; 219:285-294.","DOI":"10.1016\/j.jamcollsurg.2014.01.063"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Lau WY, Lai EC, Lau SH. Associating liver partition and portal vein ligation for staged hepatectomy: the current role and development. Hepatobiliary Pancreat Dis Int. 2017; 16:17-26.","DOI":"10.1016\/S1499-3872(16)60174-1"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Robles R, Parrilla P, L\u00f3pez-Conesa A, Brusadin R, de la Pe\u00f1a J, Fuster M, Garc\u00eda-L\u00f3pez JA, Hern\u00e1ndez E. Tourniquet modification of the associating liver partition and portal ligation for staged hepatectomy procedure. Br J Surg. 2014; 101:1129-1134.","DOI":"10.1002\/bjs.9547"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Gall TM, Sodergren MH, Frampton AE, Fan R, Spalding DR, Habib NA, Pai M, Jackson JE, Tait P, Jiao LR. Radio-frequency-assisted Liver Partition with Portal vein ligation (RALPP) for liver regeneration. Ann Surg. 2015; 261:e45-e46.","DOI":"10.1097\/SLA.0000000000000607"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Petrowsky H, Gy\u00f6ri G, de Oliveira M, Lesurtel M, Clavien PA. Is partial-ALPPS safer than ALPPS? A single-center experience. Ann Surg. 2015; 261:e90- e92.","DOI":"10.1097\/SLA.0000000000001087"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Linecker M, Bj\u00f6rnsson B, Stavrou GA <i>et al.<\/i> Risk Adjustment in ALPPS Is Associated With a Dramatic Decrease in Early Mortality and Morbidity. Ann Surg. 2017; 266:779-786.","DOI":"10.1097\/SLA.0000000000002446"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Sandstr\u00f6m P, R\u00f8sok BI, Sparrelid E, Larsen PN, Larsson AL, Lindell G, Schultz NA, Bj\u00f8rnbeth BA, Isaksson B, Rizell M, Bj\u00f6rnsson B. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: Results from a scandinavian multicenter randomized controlled trial (LIGRO Trial). Ann Surg. 2018; 267:833-840.","DOI":"10.1097\/SLA.0000000000002511"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. Raptis DA, Linecker M, Kambakamba P <i>et al.<\/i> Defining Benchmark Outcomes for ALPPS. Ann Surg. 2019; 270:835-841.","DOI":"10.1097\/SLA.0000000000003539"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. Linecker M, Stavrou GA, Oldhafer KJ <i>et al.<\/i> The ALPPS Risk Score: Avoiding Futile Use of ALPPS. Ann Surg. 2016; 264:763-771.","DOI":"10.1097\/SLA.0000000000001914"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. Collienne M, Neven A, Caballero C <i>et al.<\/i> EORTC 1409 GITCG\/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): Lessons learnt from real life. From paradigm to unmet need. Eur J Surg Oncol. 2023; 49:107081.","DOI":"10.1016\/j.ejso.2023.107081"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. Knitter S, Sauer L, Hillebrandt KH, Moosburner S, Fehrenbach U, Auer TA, Raschzok N, Lurje G, Krenzien F, Pratschke J, Sch\u00f6ning W. Extended right hepatectomy following clearance of the left liver lobe and portal vein embolization for curatively intended treatment of extensive bilobar colorectal liver metastases: A single-center case series. Curr Oncol. 2024; 31:1145-1161.","DOI":"10.3390\/curroncol31030085"},{"key":"113","doi-asserted-by":"crossref","unstructured":"113. Bednarsch J, Czigany Z, Sharmeen S, van der Kroft G, Strnad P, Ulmer TF, Isfort P, Bruners P, Lurje G, Neumann UP. ALPPS versus two-stage hepatectomy for colorectal liver metastases--a comparative retrospective cohort study. World J Surg Oncol. 2020; 18:140.","DOI":"10.1186\/s12957-020-01919-3"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. D\u00edaz Vico T, Granero Castro P, Alcover Navarro L, Su\u00e1rez S\u00e1nchez A, Mihic G\u00f3ngora L, Montalv\u00e1 Or\u00f3n EM, Maupoey Ib\u00e1\u00f1ez J, Tru\u00e1n Alonso N, Gonz\u00e1lez-Pinto Arrillaga I, Granero Tranc\u00f3n JE. Two stage hepatectomy (TSH) versus ALPPS for initially unresectable colorectal liver metastases: A systematic review and meta-analysis. Eur J Surg Oncol. 2023; 49:550-559.","DOI":"10.1016\/j.ejso.2022.11.010"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. Guiu B, Chevallier P, Denys A, Delhom E, Pierredon-Foulongne MA, Rouanet P, Fabre JM, Quenet F, Herrero A, Panaro F, Baudin G, Ramos J. Simultaneous transhepatic portal and hepatic vein embolization before major hepatectomy: the liver venous deprivation technique. Eur Radiol. 2016; 26:4259-4267.","DOI":"10.1007\/s00330-016-4291-9"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. Cassese G, Troisi RI, Khayat S, Quenet F, Tomassini F, Panaro F, Guiu B. Liver venous deprivation versus associating liver partition and portal vein ligation for staged hepatectomy for colo-rectal liver metastases: a comparison of early and late kinetic growth rates, and perioperative and oncological outcomes. Surg Oncol. 2022; 43:101812.","DOI":"10.1016\/j.suronc.2022.101812"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. Sui CJ, Cao L, Li B, Yang JM, Wang SJ, Su X, Zhou YM. Anatomical versus nonanatomical resection of colorectal liver metastases: a meta-analysis. Int J Colorectal Dis. 2012; 27:939-946.","DOI":"10.1007\/s00384-011-1403-5"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. Torzilli G, Montorsi M, Del Fabbro D, Palmisano A, Donadon M, Makuuchi M. Ultrasonographically guided surgical approach to liver tumours involving the hepatic veins close to the caval confluence. Br J Surg. 2006; 93:1238-1246.","DOI":"10.1002\/bjs.5321"},{"key":"119","doi-asserted-by":"crossref","unstructured":"119. Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C. Parenchymal-sparing Hepatectomy in Colorectal Liver Metastasis Improves Salvageability and Survival. Ann Surg. 2016; 263:146-152.","DOI":"10.1097\/SLA.0000000000001194"},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M, Matsubara T, Takahashi T, Nakajima T, Muto T. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg. 2001; 181:153-159.","DOI":"10.1016\/S0002-9610(00)00560-2"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg. 2002; 235:863-871.","DOI":"10.1097\/00000658-200206000-00015"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. Wang K, Liu Y, Hao M, Li H, Liang X, Yuan D, Ding L. Clinical outcomes of parenchymal-sparing versus anatomic resection for colorectal liver metastases: A systematic review and meta-analysis. World J Surg Oncol. 2023; 21:241.","DOI":"10.1186\/s12957-023-03127-1"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. Buell JF, Cherqui D, Geller DA <i>et al.<\/i> The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg. 2009; 250:825-830.","DOI":"10.1097\/SLA.0b013e3181b3b2d8"},{"key":"124","doi-asserted-by":"publisher","unstructured":"124. Aghayan D, Fretland \u00c5, Kazaryan A, Dagenborg V, Fagerland M, Flatmark K, Edwin B. 411P Laparoscopic versus open liver resection for colorectal cancer liver metastases: Five-year actual survival of the previously reported randomized controlled trial \u2013 The OSLO-COMET Trial. Ann Oncol. 2022; 33(Suppl): S724. http:\/\/ dx.doi.org\/10.1016\/j.annonc.2022.07.549","DOI":"10.1016\/j.annonc.2022.07.549"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. Robles-Campos R, Lopez-Lopez V, Brusadin R, Lopez-Conesa A, Gil-Vazquez PJ, Navarro-Barrios \u00c1, Parrilla P. Open versus minimally invasive liver surgery for colorectal liver metastases (LapOpHuva): a prospective randomized controlled trial. Surg Endosc. 2019; 33:3926-3936.","DOI":"10.1007\/s00464-019-06679-0"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. Tsung A, Geller DA, Sukato DC, Sabbaghian S, Tohme S, Steel J, Marsh W, Reddy SK, Bartlett DL. Robotic versus laparoscopic hepatectomy: a matched comparison. Ann Surg. 2014; 259:549-555.","DOI":"10.1097\/SLA.0000000000000250"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. Masetti M, Fallani G, Ratti F, Ferrero A, Giuliante F, Cillo U, Guglielmi A, Ettorre GM, Torzilli G, Vincenti L, Ercolani G, Cipressi C, Lombardi R, Aldrighetti L, Jovine E. Minimally invasive treatment of colorectal liver metastases: does robotic surgery provide any technical advantages over laparoscopy? A multicenter analysis from the IGoMILS (Italian Group of Minimally Invasive Liver Surgery) registry. Updates Surg. 2022; 74:535-545.","DOI":"10.1007\/s13304-022-01245-1"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. Vreeland TJ, Collings AT, Ozair A <i>et al.<\/i> SAGES\/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM). Surg Endosc. 2023; 37:2508-2516.","DOI":"10.1007\/s00464-023-09895-x"},{"key":"129","doi-asserted-by":"crossref","unstructured":"129. Tohme S, Goswami J, Han K, Chidi AP, Geller DA, Reddy S, Gleisner A, Tsung A. Minimally invasive resection of colorectal cancer liver metastases leads to an earlier initiation of chemotherapy compared to open surgery. J Gastrointest Surg. 2015; 19:2199-2206.","DOI":"10.1007\/s11605-015-2962-5"},{"key":"130","unstructured":"130. Goh BKP, Han H-S, Chen K-H <i>et al.<\/i> Defining Global Benchmarks for Laparoscopic Liver Resections: An International Multicenter Study. Ann Surg. 2023; 277:e839-e848."},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. Tan HL, Lee M, Vellayappan BA, Neo WT, Yong WP. The Role of Liver-Directed Therapy in Metastatic Colorectal Cancer. Curr Colorectal Cancer Rep. 2018; 14:129-137.","DOI":"10.1007\/s11888-018-0409-6"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. Pak LM, Kemeny NE, Capanu M, Chou JF, Boucher T, Cercek A, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D&apos;Angelica MI. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. J Surg Oncol. 2018; 117:634-643.","DOI":"10.1002\/jso.24898"},{"key":"133","doi-asserted-by":"crossref","unstructured":"133. Go\u00e9r\u00e9 D, Pignon JP, Gelli M, Elias D, Benhaim L, Deschamps F, Caramella C, Boige V, Ducreux M, de Baere T, Malka D. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II\/III trial - PACHA-01 (NCT02494973). BMC Cancer. 2018; 18:787.","DOI":"10.1186\/s12885-018-4697-7"},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. Kemeny NE, Chou JF, Boucher TM, Capanu M, DeMatteo RP, Jarnagin WR, Allen PJ, Fong YC, Cercek A, D&apos;Angelica MI. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016; 113:477-484.","DOI":"10.1002\/jso.24189"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135. Macbeth F, Farewell V, Treasure T. RE: Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst. 2017; 109.","DOI":"10.1093\/jnci\/djx149"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. Leung U, Kuk D, D&apos;Angelica MI, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, Fong Y. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg. 2015; 102:85-91.","DOI":"10.1002\/bjs.9649"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. Karagkounis G, McIntyre SM, Wang T, Chou JF, Nasar N, Gonen M, Balachandran VP, Wei AC, Soares KC, Drebin JA, D&apos;Angelica MI, Jarnagin WR, Kingham TP. Rates and patterns of recurrence after microwave ablation of colorectal liver metastases: A per lesion analysis of 416 tumors in the era of 2.45 GHz generators. Ann Surg Oncol. 2023; 30:6571-6578.","DOI":"10.1245\/s10434-023-13751-6"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. Tinguely P, Ruiter SJS, Engstrand J, de Haas RJ, Nilsson H, Candinas D, de Jong KP, Freedman J. A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC). Eur J Cancer. 2023; 187:65-76.","DOI":"10.1016\/j.ejca.2023.03.038"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. Meijerink MR, van der Lei S, Dijkstra M <i>et al.<\/i> Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. Lancet Oncol. 2025; 26:187-199.","DOI":"10.1016\/S1470-2045(24)00660-0"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. Tinguely P, Laurell G, Enander A, Engstrand J, Freedman J.Ablation versus resection for resectable colorectal liver metastases - Health care related cost and survival analyses from a quasi-randomised study. Eur J Surg Oncol. 2023; 49:416-425.","DOI":"10.1016\/j.ejso.2022.09.006"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141. Liu M, Wang Y, Wang K, Bao Q, Wang H, Jin K, Liu W, Yan X, Xing B. Combined ablation and resection (CARe) for resectable colorectal cancer liver Metastases-A propensity score matching study. Eur J Surg Oncol. 2023; 49:106931.","DOI":"10.1016\/j.ejso.2023.05.006"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142. Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, Mancosu P, Reggiori G, Rimassa L, Torzilli G, Tomatis S, Santoro A, Cozzi L. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015; 141:543-553.","DOI":"10.1007\/s00432-014-1833-x"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. van Hazel GA, Heinemann V, Sharma NK <i>et al.<\/i> SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34:1723-1731.","DOI":"10.1200\/JCO.2015.66.1181"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper MJ, Feng M, Cuneo KC, Lawrence TS, Owen D. Comparison of Stereotactic Body Radiation Therapy and Radiofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J Radiat Oncol Biol Phys. 2018; 100:950-958.","DOI":"10.1016\/j.ijrobp.2017.12.014"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145. Ruers T, Punt CJA, van Coevorden F, Pierie JP, Rinkes IB, Ledermann JA, Poston GJ, Bechstein WO, Lentz MA, Mauer ME, Cutsem EV, Lutz MP, Nordlinger B. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Orthod. 2015; 33:3501. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.3501","DOI":"10.1200\/jco.2015.33.15_suppl.3501"},{"key":"146","doi-asserted-by":"crossref","unstructured":"146. Giannone F, Grollemund A, Felli E, Mayer T, Cherkaoui Z, Schuster C, Pessaux P. Combining radiofrequency ablation with hepatic resection for liver-only colorectal metastases: A propensity-score based analysis of long-term outcomes. Ann Surg Oncol. 2023; 30:4856-4866.","DOI":"10.1245\/s10434-023-13530-3"},{"key":"147","doi-asserted-by":"crossref","unstructured":"147. de Graaff MR, Klaase JM, den Dulk M <i>et al.<\/i> Trends and overall survival after combined liver resection and thermal ablation of colorectal liver metastases: a nationwide population-based propensity score-matched study. HPB (Oxford). 2024; 26:34-43.","DOI":"10.1016\/j.hpb.2024.03.114"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010; 14:1691-1700.","DOI":"10.1007\/s11605-010-1348-y"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149. Papakonstantinou M, Fantakis A, Torzilli G, Donadon M, Chatzikomnitsa P, Giakoustidis D, Papadopoulos VN, Giakoustidis A. A systematic review of disappearing colorectal liver metastases: Resection or no resection? J Clin Med. 2025; 14:1147.","DOI":"10.3390\/jcm14041147"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150. Tani K, Shindoh J, Akamatsu N, Arita J, Kaneko J, Sakamoto Y, Hasegawa K, Kokudo N. Management of disappearing lesions after chemotherapy for colorectal liver metastases: Relation between detectability and residual tumors. J Surg Oncol. 2018; 117:191-197.","DOI":"10.1002\/jso.24805"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151. Kuhlmann K, van Hilst J, Fisher S, Poston G. Management of disappearing colorectal liver metastases. Eur J Surg Oncol. 2016; 42:1798-1805.","DOI":"10.1016\/j.ejso.2016.05.005"},{"key":"152","doi-asserted-by":"crossref","unstructured":"152. Anselmo A, Cascone C, Siragusa L, Sensi B, Materazzo M, Riccetti C, Bacchiocchi G, Ielpo B, Rosso E, Tisone G. Disappearing colorectal liver metastases: Do we really need a ghostbuster? Healthcare (Basel). 2022; 10:1898.","DOI":"10.3390\/healthcare10101898"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153. Barimani D, Kauppila JH, Sturesson C, Sparrelid E. Imaging in disappearing colorectal liver metastases and their accuracy: a systematic review. World J Surg Oncol. 2020; 18:264.","DOI":"10.1186\/s12957-020-02037-w"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154. Ghazanfar MA, Abdelhamid A, Aldrighetti L <i>et al.<\/i> The dilemma of the disappearing colorectal liver metastases: defining international trends in management. HPB (Oxford). 2023; 25:446-453.","DOI":"10.1016\/j.hpb.2023.01.003"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155. Owen JW, Fowler KJ, Doyle MB, Saad NE, Linehan DC, Chapman WC. Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB (Oxford). 2016; 18:296-303.","DOI":"10.1016\/j.hpb.2015.10.009"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156. Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, Bj\u00f8rnbeth BA, Hagness M, Line PD. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg. 2020; 271:212-218.","DOI":"10.1097\/SLA.0000000000003404"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157. Adam R, Piedvache C, Chiche L <i>et al.<\/i> Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet. 2024; 404:1107-1118.","DOI":"10.2139\/ssrn.4830489"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158. Maspero M, Sposito C, Virdis M, Citterio D, Pietrantonio F, Bhoori S, Belli F, Mazzaferro V. Liver transplantation for hepatic metastases from colorectal cancer: Current knowledge and open issues. Cancers (Basel). 2023; 15:345.","DOI":"10.3390\/cancers15020345"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159. Ch\u00e1vez-Villa M, Ruffolo LI, Line PD, Dueland S, Tomiyama K, Hernandez-Alejandro R. Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases. J Clin Oncol. 2024; 42:1098-1101.","DOI":"10.1200\/JCO.23.01781"},{"key":"160","doi-asserted-by":"crossref","unstructured":"160. Line PD, Dueland S. Transplantation for colorectal liver metastasis. Curr Opin Organ Transplant. 2024; 29:23-29.","DOI":"10.1097\/MOT.0000000000001126"},{"key":"161","doi-asserted-by":"crossref","unstructured":"161. Line PD, Dueland S. Liver transplantation for secondary liver tumours: The difficult balance between survival and recurrence. J Hepatol. 2020; 73:1557-1562.","DOI":"10.1016\/j.jhep.2020.08.015"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162. Lanari J, Hagness M, Sartori A, Rosso E, Gringeri E, Dueland S, Cillo U, Line PD. Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score. Transpl Int. 2021; 34:1722-1732.","DOI":"10.1111\/tri.13981"},{"key":"163","doi-asserted-by":"crossref","unstructured":"163. Nadalin S, Settmacher U, Rauchfu\u00df F, Balci D, K\u00f6nigsrainer A, Line PD. RAPID procedure for colorectal cancer liver metastasis. Int J Surg. 2020; 82S:93-96.","DOI":"10.1016\/j.ijsu.2020.03.078"},{"key":"164","doi-asserted-by":"crossref","unstructured":"164. S\u00f8reide K. Liver transplantation for non-resectable colorectal liver metastases: The thin red line. Br J Cancer. 2023; 128:1794-1796.","DOI":"10.1038\/s41416-023-02234-w"},{"key":"165","doi-asserted-by":"crossref","unstructured":"165. Adam R, Accardo C, Allard MA. Cytoreductive surgery for colorectal liver metastases: is it worthwhile? Minerva Surg. 2022; 77:433-440.","DOI":"10.23736\/S2724-5691.22.09669-1"},{"key":"166","doi-asserted-by":"crossref","unstructured":"166. Adam R, Kitano Y, Abdelrafee A, Allard MA, Baba H. Debulking surgery for colorectal liver metastases: Foolish or chance? Surg Oncol. 2020; 33:266-269.","DOI":"10.1016\/j.suronc.2020.02.008"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167. Kalil JA, Krzywon L, Zlotnik O, Perrier H, Petrillo SK, Chaudhury P, Schadde E, Metrakos P. Debulking hepatectomy for colorectal liver metastasis conveys survival benefit. Cancers (Basel). 2024; 16:1730.","DOI":"10.3390\/cancers16091730"},{"key":"168","doi-asserted-by":"crossref","unstructured":"168. Stewart CL, Warner S, Ito K, Raoof M, Wu GX, Kessler J, Kim JY, Fong Y. Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr Probl Surg. 2018; 55:330-379.","DOI":"10.1067\/j.cpsurg.2018.08.004"},{"key":"169","doi-asserted-by":"crossref","unstructured":"169. Rompianesi G, Pegoraro F, Ceresa CD, Montalti R, Troisi RI. Artificial intelligence in the diagnosis and management of colorectal cancer liver metastases. World J Gastroenterol. 2022; 28:108-122.","DOI":"10.3748\/wjg.v28.i1.108"},{"key":"170","doi-asserted-by":"crossref","unstructured":"170. Han T, Zhu J, Chen X, Chen R, Jiang Y, Wang S, Xu D, Shen G, Zheng J, Xu C. Application of artificial intelligence in a real-world research for predicting the risk of liver metastasis in T1 colorectal cancer. Cancer Cell Int. 2022; 22:28.","DOI":"10.1186\/s12935-021-02424-7"},{"key":"171","doi-asserted-by":"crossref","unstructured":"171. Li M, Li X, Guo Y, Miao Z, Liu X, Guo S, Zhang H. Development and assessment of an individualized nomogram to predict colorectal cancer liver metastases. Quant Imaging Med Surg. 2020; 10:397-414.","DOI":"10.21037\/qims.2019.12.16"},{"key":"172","doi-asserted-by":"crossref","unstructured":"172. Wesdorp NJ, van Goor VJ, Kemna R, Jansma EP, van Waesberghe JHTM, Swijnenburg RJ, Punt CJA, Huiskens J, Kazemier G. Advanced image analytics predicting clinical outcomes in patients with colorectal liver metastases: A systematic review of the literature. Surg Oncol. 2021; 38:101578.","DOI":"10.1016\/j.suronc.2021.101578"},{"key":"173","doi-asserted-by":"crossref","unstructured":"173. Wei J, Cheng J, Gu D, Chai F, Hong N, Wang Y, Tian J. Deep learning-based radiomics predicts response to chemotherapy in colorectal liver metastases. Med Phys. 2021; 48:513-522.","DOI":"10.1002\/mp.14563"},{"key":"174","doi-asserted-by":"crossref","unstructured":"174. Taghavi M, Staal F, Gomez Munoz F, Imani F, Meek DB, Sim\u00f5es R, Klompenhouwer LG, van der Heide UA, Beets-Tan RGH, Maas M. CT-Based Radiomics Analysis Before Thermal Ablation to Predict Local Tumor Progression for Colorectal Liver Metastases. Cardiovasc Intervent Radiol. 2021; 44:913-920.","DOI":"10.1007\/s00270-020-02735-8"},{"key":"175","doi-asserted-by":"crossref","unstructured":"175. Bertsimas D, Margonis GA, Sujichantararat S <i>et al.<\/i> Using Artificial Intelligence to Find the Optimal Margin Width in Hepatectomy for Colorectal Cancer Liver Metastases. JAMA Surg. 2022; 157:e221819.","DOI":"10.1001\/jamasurg.2022.1819"},{"key":"176","doi-asserted-by":"crossref","unstructured":"176. Kawashima J, Endo Y, Woldesenbet S <i>et al.<\/i> Preoperative identification of early extrahepatic recurrence after hepatectomy for colorectal liver metastases: A machine learning approach. World J Surg. 2024; 48:2760-2771.","DOI":"10.1002\/wjs.12376"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177. Dohan A, Gallix B, Guiu B <i>et al.<\/i> Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut. 2020; 69:531-539.","DOI":"10.1136\/gutjnl-2018-316407"},{"key":"178","doi-asserted-by":"crossref","unstructured":"178. Gr\u00fcnhagen D. Predicting prognosis in colorectal liver metastases. Hepatobiliary Surg Nutr. 2019; 8:643-645.","DOI":"10.21037\/hbsn.2019.07.10"},{"key":"179","doi-asserted-by":"crossref","unstructured":"179. Ma YS, Huang T, Zhong XM, Zhang HW, Cong XL, Xu H, Lu GX, Yu F, Xue SB, Lv ZW, Fu D. Proteogenomic characterization and comprehensive integrative genomic analysis of human colorectal cancer liver metastasis. Mol Cancer. 2018; 17:139.","DOI":"10.1186\/s12943-018-0890-1"},{"key":"180","doi-asserted-by":"crossref","unstructured":"180. Kawaguchi Y, Lillemoe HA, Vauthey JN. Gene mutation and surgical technique: Suggestion or more? Surg Oncol. 2020; 33:210-215.","DOI":"10.1016\/j.suronc.2019.07.004"},{"key":"181","doi-asserted-by":"crossref","unstructured":"181. Jiang BB, Yan K, Zhang ZY, Yang W, Wu W, Yin SS, Chen MH. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation. Int J Hyperthermia. 2019; 36:211-219.","DOI":"10.1080\/02656736.2018.1556818"},{"key":"182","doi-asserted-by":"crossref","unstructured":"182. Odisio BC, Yamashita S, Huang SY, Harmoush S, Kopetz SE, Ahrar K, Shin Chun Y, Conrad C, Aloia TA, Gupta S, Hicks ME, Vauthey JN. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg. 2017; 104:760-768.","DOI":"10.1002\/bjs.10490"},{"key":"183","doi-asserted-by":"crossref","unstructured":"183. Brudvik KW, Mise Y, Chung MH, Chun YS, Kopetz SE, Passot G, Conrad C, Maru DM, Aloia TA, Vauthey JN. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases. Ann Surg Oncol. 2016; 23:2635-43.","DOI":"10.1245\/s10434-016-5187-2"},{"key":"184","doi-asserted-by":"crossref","unstructured":"184. Kawaguchi Y, Kopetz S, Newhook TE, De Bellis M, Chun YS, Tzeng CD, Aloia TA, Vauthey JN. Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases. Clin Cancer Res. 2019; 25:5843-5851.","DOI":"10.1158\/1078-0432.CCR-19-0863"},{"key":"185","doi-asserted-by":"crossref","unstructured":"185. Katipally RR, Martinez CA, Pugh SA, Bridgewater JA, Primrose JN, Domingo E, Maughan TS, Talamonti MS, Posner MC, Weichselbaum RR, Pitroda SP; with the S:CORT Consortium. Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023; 9:1245-1254.","DOI":"10.1001\/jamaoncol.2023.2535"},{"key":"186","doi-asserted-by":"crossref","unstructured":"186. Patsalias A, Kozovska Z. Personalized medicine: Stem cells in colorectal cancer treatment. Biomed Pharmacother. 2021; 141:111821.","DOI":"10.1016\/j.biopha.2021.111821"},{"key":"187","doi-asserted-by":"crossref","unstructured":"187. Garza Trevi\u00f1o EN, Quiroz Reyes AG, Rojas Murillo JA, de la Garza Kalife DA, Delgado Gonzalez P, Islas JF, Estrada Rodriguez AE, Gonzalez Villarreal CA. Cell therapy as target therapy against colon cancer stem cells. Int J Mol Sci. 2023; 24:8163.","DOI":"10.3390\/ijms24098163"}],"container-title":["BioScience Trends"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/3\/19_2025.01012\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:32:11Z","timestamp":1751689931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bst\/19\/3\/19_2025.01012\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":187,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/bst.2025.01012","relation":{},"ISSN":["1881-7815","1881-7823"],"issn-type":[{"value":"1881-7815","type":"print"},{"value":"1881-7823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"article-number":"2025.01012"}}